What is the dosage of Fezonatant? How should patients use this drug correctly according to their doctor's recommendations?
Fezolinetant (Fezolinetant) is a selective neurokinin 3 (NK3) receptor antagonist, mainly used to relieve moderate to severe vasomotor symptoms (VMS) in postmenopausal women, such as hot flashes and night sweats. It modulates the temperature control center of the brain's hypothalamus by blocking the NK3 NK3 receptor, thereby reducing the symptoms of hot flashes caused by decreased estrogen levels.
The recommended dose is 45 mg once daily orally, with a meal or on an empty stomach. Patients are advised to take the medication at the same time every day to maintain stable medication effects. If you accidentally miss a dose, you can take it as soon as possible if the interval is short; but if it is close to the next dose time, you should skip the missed dose and do not increase the dose yourself to avoid increasing the risk of side effects.

While taking fezonatant, patients should follow their doctor's recommendations and have regular follow-up visits, especially patients with liver disease or other chronic diseases who may need dose adjustments or additional monitoring. This drug is mainly metabolized by the liver. Patients with impaired liver function should use it under the guidance of a doctor to reduce the risk of drug accumulation. In addition, patients should inform their doctor about all medications they are taking to avoid potential drug interactions, such as certain CYP450 enzyme inhibitors that may affect the metabolism of fezonetant.
Although fezonatant is effective in relieving the symptoms of hot flashes, some patients may experience side effects such as headache, nausea, fatigue, or elevated liver enzymes. If you experience severe discomfort, such as persistent headache, obvious fatigue or other abnormal symptoms, you should seek medical attention immediately. While taking the medication, patients should maintain a healthy lifestyle, such as a balanced diet and moderate exercise, to enhance overall health and further improve menopausal-related symptoms.
Reference materials:https://www.veozah.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)